How Agaricus blazei Activates NK Cells

Agaricus blazei and Immune Function

P < 0.002 NK Activity

In 100 gynecological cancer patients undergoing chemotherapy, those who received Agaricus blazei extract had significantly higher natural killer cell activity compared to the chemotherapy-only group.

Ahn et al., International Journal of Gynecological Cancer, 2004

100 Patients

cervical, ovarian, endometrial cancer

IL-12 Dependent

NK activation requires IL-12 and IFN-gamma

Selective Kill

tumoricidal for cancer cells, spares normal cells

Ahn et al., International Journal of Gynecological Cancer, 2004

View as image ↗

Natural killer cells are the immune system's first responders against cancer. Unlike T cells, which need to be trained to recognize specific tumor antigens, NK cells can detect and kill abnormal cells without prior sensitization. They patrol the body, identify cells with missing or altered surface markers (a hallmark of cancer and viral infection), and destroy them through direct cytotoxic action. When NK cell activity drops, as it does during chemotherapy, immune surveillance weakens and tumors can grow unchecked.

Agaricus blazei Murill (ABM) is one of the most studied medicinal mushrooms for NK cell activation. Research spanning from 1998 to 2015 has mapped the pathway: ABM beta-glucans bind to receptors on dendritic cells, which produce IL-12, which triggers IFN-gamma production, which activates NK cells. This chain has been demonstrated in vitro, in multiple mouse strains, and in human cancer patients. The broader question of whether Agaricus blazei is the most immunostimulating mushroom requires comparison across species, but the NK cell data for ABM is among the strongest for any single mushroom.

What NK Cells Do and Why They Matter

NK cells are large granular lymphocytes that make up 5-15% of circulating blood lymphocytes. They belong to the innate immune system, meaning they respond to threats without needing prior exposure or antigen presentation. Their name reflects their function: they kill on contact.

NK cells use two main strategies to identify targets. First, they detect the absence of MHC class I molecules on cell surfaces. Normal cells display MHC I; cancer cells and virus-infected cells often downregulate MHC I to evade T cell detection. NK cells read this absence as a kill signal (the "missing self" hypothesis). Second, NK cells express activating receptors (like NKG2D) that recognize stress ligands displayed on damaged or transformed cells.

Once activated, NK cells release perforin (which punches holes in target cell membranes) and granzymes (proteases that trigger apoptosis inside the target cell). They also produce IFN-gamma, which activates macrophages and enhances the broader immune response.

In cancer patients, NK cell activity is often suppressed by the tumor microenvironment and by chemotherapy itself. Chemotherapy drugs kill rapidly dividing cells indiscriminately, including immune cells. Restoring NK cell function during or after chemotherapy is a legitimate therapeutic goal, which is what makes the ABM research relevant.

The Fujimiya Study: Selective Tumor Killing (1998)

The foundational NK cell study for ABM was published by Fujimiya and colleagues in 1998.^[1] Using a double-grafted tumor system in BALB/c mice, they demonstrated that an acid-treated fraction (ATF) from ABM fruit bodies caused NK cells to infiltrate and attack distant tumors.

The key findings:

• NK cell infiltration: Treatment of a primary tumor with ATF resulted in NK cells infiltrating a distant (untreated) tumor and killing cancer cells
• Selective cytotoxicity: ATF directly inhibited tumor cell growth in vitro through apoptosis, but had no effect on normal mouse splenic mononuclear cells
• Cell cycle arrest: ATF caused loss of S phase in MethA tumor cells while normal cells (in G0/G1 phase) were unaffected
• Active compounds identified: The tumoricidal activity was chiefly in fractions containing (1-4)-alpha-D-glucan and (1-6)-beta-D-glucan, with the most active fraction (HM3-G, 380 kDa) consisting of more than 90% glucose

The selectivity is important. ATF killed tumor cells while leaving normal cells alone. This is not true of most chemotherapy drugs, which kill all rapidly dividing cells. The mechanism involves apoptosis induction (increased Apo2.7 antigen expression on mitochondrial membranes) rather than necrosis, meaning programmed cell death rather than inflammatory cell destruction.

The Mechanism: IL-12, IFN-gamma, and Dendritic Cells

Yuminamochi and colleagues published the definitive mechanistic study in 2007, mapping exactly how ABM activates NK cells.^[2]

They tested oral ABM administration across multiple mouse strains (C57BL/6, C3H/HeJ, BALB/c) and found consistent NK cell activation in all wild-type mice. The critical experiment used knockout mice:

• IFN-gamma-deficient mice: NK cell augmentation was completely absent, proving that IFN-gamma is required for ABM-mediated NK activation
• RAG-2-deficient mice (which lack T and B cells but retain NK cells): NK cell augmentation still occurred, proving that T and B cells are not required

The pathway works through dendritic cells. When dendritic cell-rich splenocytes were co-incubated with ABM extract in vitro, both NK cell activation and IFN-gamma production occurred. Anti-IL-12 monoclonal antibodies largely inhibited both effects. Combining anti-IL-12 with anti-IL-18 antibodies completely abolished them.

The complete signaling chain: ABM beta-glucans activate dendritic cells via pattern recognition receptors. Dendritic cells produce IL-12 (and IL-18). IL-12 stimulates NK cells to produce IFN-gamma. IFN-gamma feeds back to further activate NK cells, creating an amplification loop. For the role of Toll-like receptors in this process, the receptor biology is covered in a dedicated article.

Dendritic Cells: The Missing Link

Forland and colleagues filled in a critical piece of the puzzle in 2010 by examining what happens when ABM extract meets dendritic cells directly.^[3] They incubated human monocyte-derived dendritic cells (MDDC) with the ABM-based extract AndoSan.

The cytokine response was remarkable. ABM extract induced dose-dependent increases in:

• IL-8 (neutrophil recruitment)
• G-CSF (granulocyte colony-stimulating factor)
• TNF-alpha (inflammatory signaling)
• IL-1beta (inflammatory signaling)
• IL-6 (immune activation)
• MIP-1beta (macrophage inflammatory protein)

When compared to bacterial lipopolysaccharide (LPS), a potent known immune activator, ABM extract induced 10-fold more G-CSF and 2-fold more TNF-alpha. For IL-2, IL-8, and IFN-gamma, ABM and LPS were comparable.

ABM did not induce Th2 (anti-inflammatory) cytokines, and it did not induce IL-12 from dendritic cells in this particular in vitro system. This seems to contradict the Yuminamochi findings, but the discrepancy likely reflects differences between isolated dendritic cell cultures and the intact splenocyte environment where multiple cell types interact. IL-12 production may require cross-talk between dendritic cells and other immune cells that was absent in the purified MDDC system.

The Dectin-1 Receptor: How Beta-Glucans Are Recognized

Lee and Kim published a comprehensive review in 2014 explaining how fungal beta-glucans trigger innate immune responses through the Dectin-1 signaling pathway.^[4]

Innate immune cells express pattern recognition receptors (PRRs) on their surfaces, including Dectin-1, Toll-like receptors, and mannose receptors. These PRRs recognize pathogen-associated molecular patterns (PAMPs) such as beta-glucan, mannan, and lipopolysaccharide.

When beta-glucans bind Dectin-1 on macrophages or dendritic cells:

1. Intracellular signaling cascades activate (Syk kinase, CARD9, NF-kB)
2. Cytokines are released (IL-4, IL-6, TNF-alpha)
3. Adaptive immune cells are activated downstream (B cells, T cells, NK cells)

Water-insoluble beta-glucans (like those in ABM fruiting bodies) have stronger immunostimulating activity than water-soluble forms. This structural detail explains why extraction method matters for ABM's biological activity and why some studies using aqueous extracts show weaker effects than those using whole mushroom preparations or organic extracts. The broader question of how ABM might enhance vaccine responses builds on this same receptor biology.

Human Clinical Evidence

Gynecological Cancer: Ahn 2004

The largest human trial measuring NK cell activity with ABM enrolled 100 patients with cervical, ovarian, or endometrial cancer receiving standard chemotherapy.^[5] Thirty-nine patients received oral ABM extract (ABMK); 61 served as controls.

NK cell activity was statistically significantly higher in the ABM group (P < 0.002 by ANOVA). Lymphokine-activated killer (LAK) cell activity and monocyte activity were not significantly different between groups, suggesting ABM's effect is specific to NK cells rather than a general immune boost.

Side effects of chemotherapy were also reduced: appetite, hair loss severity, emotional stability, and general weakness all improved in the ABM group. Whether this reflects immune-mediated benefits or other pharmacological effects of ABM is unknown.

The study was not randomized. Patients chose whether to take ABM alongside chemotherapy, introducing selection bias. The unequal group sizes (39 vs. 61) further complicate interpretation. But the statistical significance of the NK cell finding, combined with the mechanistic data from animal studies, makes a plausible case for a real effect. The specific implications for immune-compromised patients beyond cancer are explored separately.

Multiple Myeloma: Tangen 2015

The strongest clinical evidence comes from a randomized, double-blind trial of 40 multiple myeloma patients undergoing high-dose chemotherapy with autologous stem cell transplantation.^[6] Patients received either AndoSan (82% ABM) or placebo for approximately seven weeks, starting on the day of stem cell mobilization.

In the leukapheresis product (harvested stem cells), the ABM group showed:

• Increased Treg cell percentages
• Increased plasmacytoid dendritic cells
• Elevated serum IL-1ra, IL-5, and IL-7 at treatment end
• Increased expression of immunoglobulin genes, KIR genes, and HLA genes on whole genome microarray

KIR (Killer Immunoglobulin Receptor) genes are directly relevant to NK cell function. KIRs regulate NK cell activation by interacting with MHC class I molecules on target cells. Upregulation of KIR gene expression suggests ABM is priming NK cells for enhanced surveillance.

AndoSan also showed concentration-dependent antiproliferative effects on mouse myeloma cells in vitro. But there were no statistically significant differences in treatment response, overall survival, or time to new treatment between groups. The immune biomarkers changed; the clinical cancer outcomes did not, at least within the study's follow-up period and sample size.

Limitations of the Evidence

Hetland and colleagues noted in their 2008 review that ABM extracts from different sources and manufacturing processes show "highly different biological potency."^[7] This means that results from one ABM product (AndoSan, ABMK, or laboratory preparations) may not generalize to other products.

The mouse studies are consistent and mechanistically clear. The human studies show immune biomarker changes but not clinical outcome improvements. This gap is the central limitation: NK cell activity is a surrogate marker, not a patient outcome. Higher NK cell activity does not automatically mean fewer cancers, longer survival, or faster recovery.

Hetland's 2011 review summarized the state of evidence: ABM stimulates innate immune cells (monocytes, NK cells, dendritic cells) and ameliorates Th1/Th2 imbalance in mouse models.^[8] These effects have been shown to have antitumor, anti-infection, and antiallergic properties in animal models and anti-inflammatory effects in inflammatory bowel disease patients. Translating these immune effects into measurable clinical cancer outcomes remains unfinished work.

The Bottom Line

Agaricus blazei activates NK cells through a mapped IL-12/IFN-gamma pathway originating at dendritic cell Dectin-1 receptors. Mouse studies show selective tumor killing with NK cell infiltration. The largest human trial (100 cancer patients) found significantly elevated NK cell activity (P < 0.002), and a randomized trial in 40 myeloma patients showed upregulation of KIR genes. Neither human trial demonstrated improved cancer outcomes, leaving a gap between immune activation and clinical benefit.

Frequently Asked Questions

Does Agaricus blazei increase NK cell activity?

Yes, in both animal and human studies. In 100 gynecological cancer patients, oral ABM extract significantly increased NK cell activity (P < 0.002) compared to chemotherapy alone (Ahn et al., 2004). Mouse studies show the mechanism requires IL-12 from dendritic cells and IFN-gamma from NK cells, creating an amplification loop (Yuminamochi et al., 2007).

How does Agaricus blazei activate the immune system?

ABM beta-glucans bind to Dectin-1 receptors on macrophages and dendritic cells. This triggers cytokine production (IL-12, IL-18, TNF-alpha, G-CSF) that activates NK cells, T cells, and other immune effectors. The cascade originates in the innate immune system and expands to adaptive immunity through dendritic cell signaling (Lee et al., 2014).

Can Agaricus blazei help during chemotherapy?

One non-randomized trial of 100 cancer patients found that ABM extract alongside chemotherapy increased NK cell activity and reduced side effects including appetite loss, hair loss, and weakness (Ahn et al., 2004). A randomized trial in 40 myeloma patients showed immune biomarker changes but no difference in treatment response or survival (Tangen et al., 2015). The evidence is preliminary.

What is the NK cell activation pathway for Agaricus blazei?

The mapped pathway: ABM beta-glucans bind Dectin-1 on dendritic cells, which produce IL-12. IL-12 stimulates NK cells to produce IFN-gamma. IFN-gamma amplifies NK cell cytotoxicity. This was proven using IFN-gamma knockout mice, where ABM could not activate NK cells without IFN-gamma (Yuminamochi et al., 2007).

Does Agaricus blazei kill cancer cells directly?

ABM proteoglucan fractions directly induced apoptosis in tumor cells in vitro while sparing normal cells. The active compound (HM3-G, 380 kDa) consisted primarily of alpha-D-glucan and beta-D-glucan. It caused cancer cell cycle arrest (loss of S phase) without affecting normal splenocytes (Fujimiya et al., 1998). This dual mechanism, direct apoptosis plus NK cell activation, makes ABM distinct from purely immunomodulatory agents.

Is Agaricus blazei the best mushroom for NK cell activation?

ABM has the most published evidence specifically measuring NK cell activation among medicinal mushrooms. However, other species (Ganoderma lucidum, Grifola frondosa, Lentinula edodes) also activate NK cells through beta-glucan pathways. Head-to-head comparisons are scarce. The AndoSan extract (82% ABM, 15% Hericium erinaceus, 3% Grifola frondosa) used in the myeloma trial makes it difficult to isolate ABM's contribution from other mushroom species.

Sources & References

1. 1RTHM-00025·Fujimiya, Y et al. (1998). “Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis..” Cancer immunology.Study breakdown →PubMed →↩
2. 2RTHM-00125·Yuminamochi, Eri et al. (2007). “Interleukin-12- and interferon-gamma-mediated natural killer cell activation by Agaricus blazei Murill..” Immunology.Study breakdown →PubMed →↩
3. 3RTHM-00181·Førland, D T et al. (2010). “An extract based on the medicinal mushroom Agaricus blazei Murill stimulates monocyte-derived dendritic cells to cytokine and chemokine production in vitro..” Cytokine.Study breakdown →PubMed →↩
4. 4RTHM-00333·Lee, Dong Hee et al. (2014). “Innate immunity induced by fungal β-glucans via dectin-1 signaling pathway..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
5. 5RTHM-00066·Ahn, W-S et al. (2004). “Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy..” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.Study breakdown →PubMed →↩
6. 6RTHM-00404·Tangen, Jon-Magnus et al. (2015). “Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study..” BioMed research international.Study breakdown →PubMed →↩
7. 7RTHM-00133·Hetland, G et al. (2008). “Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer..” Scandinavian journal of immunology.Study breakdown →PubMed →↩
8. 8RTHM-00215·Hetland, Geir et al. (2011). “The Mushroom Agaricus blazei Murill Elicits Medicinal Effects on Tumor, Infection, Allergy, and Inflammation through Its Modulation of Innate Immunity and Amelioration of Th1/Th2 Imbalance and Inflammation..” Advances in pharmacological sciences.Study breakdown →PubMed →↩